Changes in end products of nitric oxide in urine and induction of nitric oxide synthase expression in urinary bladder during intravesical instillations of IFN-α2b

Journal of Interferon and Cytokine Research

Volumn 24, Issue 10, 2004, Pages 621-626

  Mitropoulos, Dionisios ^a   Deliconstantinos, George ^a   Adamakis, Ioannis ^a   Zervas, Anastasios ^a   Karakaidos, Panagiotis ^a   Gorgoulis, Vassilis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; RECOMBINANT ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 4944248820     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2004.24.621     Document Type: Article

References (44)

1. PARKIN, D.M., PISANI, P., and FERLAY, J. (1999). Global cancer statistics. CA Cancer J. Clin. 49, 33-64.
2. CUTLER, S.J., HENEY, N.M., and FRIEDELL, G.H. (1982). Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: AUA monographs. Vol 1: Bladder Cancer. W.W. Bonney and G.R. Prout, Jr. (eds.) Baltimore: Williams & Wilkins, pp. 35-46.
3. HENEY, N.M., AHMED, S., FLANAGAN, M.J., FRABLE, W., CORDER, M.P., HAFERMANN, M.D., and HAWKINS, I.R. (1983). Superficial bladder cancer: progression and recurrence. J. Urol. 130, 1083-1086.
4. WITJES, J.A., MULDERS, P.F., and DEBRUYNE, F.M. (1994). Intravesical therapy in superficial bladder cancer. Urology 43 (Suppl. 2), 2-6.
5. KILBRIDGE, K.L., and KANTOFF, P. (1994). Intravesical therapy for superficial bladder cancer: is it a wash? J. Clin. Oncol. 12, 1-4.
6. KOSTAKOPOULOS, A., DELIVELIOTIS, C., MAVROMANOLAKIS, E., ARAVANTINOS, G., and DIMOPOULOS, M.A. (1990). Interferon alpha-2b administration in the treatment of superficial bladder tumors. Eur. Urol. 18, 201-205.
7. GIANNAKOPOULOS, S., GEKAS, A., ALIVIZATOS, G., SOFRAS, F., BECOPOULOS, T., and DIMOPOULOS, C. (1998). Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br. J. Urol. 82, 829-834.
8. TORTI, F.M., SHORTLIFFE, L.D., WILLIAMS, R.D., PITTS, W.C., KEMPSON, R.L., ROSS, J.C., PALMER, J., MEYERS, F., FERRARI, M., and HANNIGAN, J. (1988). Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group study. J. Clin. Oncol. 6, 476-483.
9. GLASHAN, R. (1990). A randomized controlled study of intravesical α2b interferon in carcinoma in situ of the bladder. J. Urol. 144, 658-661.
10. BOCCARDO, F., CANNATA, D., RUBAGOTTI, A., GUARNERI, D., DECENSI, A., CANOBBIO, L., CUROTTO, A., MARTORANA, G., FEGORARO, C., and SELVAGGI, P. (1994). Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J. Clin. Oncol. 12, 7-13.
11. BORDEN, E., GROVEMAN, D., NASU, T., REZNIKOFF, C., and BRYAN. G.T. (1984). Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol. 132, 800-803.
12. DIANZANI, F. (1992) Biological basis for therapy and for side effects. In: Interferon: Principles and Medical Applications. S. Boron, D.H. Coppenhaver, F. Dianzani, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas, pp. 409-416.
13. GIANNOPOULOS, A., CONSTANTINIDES, C., KORTSARIS, A., CHRISOFOS, M., PAVLAKI, C., and DIMOPOULOS, C. (1997). Determination of interferon-alpha receptors in urothelial cancer and in normal urothelium. J. Urol. 157, 79-82.
14. GIANNOPOULOS, A., ADAMAKIS, I., EVANGELOU, K., GIANNOPOULOU, M., ZACHARATOS, P., ZSANTOULIS, P., PERUNOVIC, B., ATHANASIOU, A., RETALIS, G., CONSTANTINIDES, C., and GORGOULIS, V.G. (2003). Interferon-α2b reduces neo-microvascular density adjacent to the tumor after transurethral resection of superficial bladder carcinoma. Onkologie 26, 147-152.
15. BOSTROM, P.J., UOTILA, P., RAJALA, P., NURMI, M., HUHTANIEMI, I., and LAATO, M. (2001). Interferon-a inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol. Res. 29, 20-24.
16. RHODES, J., JONES, D.H., and BLEEHEN, N.M. (1983). Increased expression of human monocyte HLA-DR antigens and Fc-gamma receptors in response to human interferon in vivo. Clin. Exp. Immunol. 53, 739-743.
17. NATSIS. K., TOLIOU, T., STRAVORAVDI, P., KIRTSIS, P., GREKOU, A., BARICH, A., KONSTANTINIDIS. E., and GIGIS, P. (1997). Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study. Int. J. Clin. Pharmacol. Res. 17, 31-36.
18. MOLTO, L., ALVAREZ-MON, M., CARBALLIDO, J., MANZANO, L., GUILLEN, C., PRIETO, A., OLIVIER, C., and RODRIGUEZ-ZAPATA, M. (1994). Intracavitary prophylactic treatment with interferon alpha2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br. J. Cancer 70, 1247-1251.
19. MOLTO, L., ALVAREZ-MON, M., CARBALLIDO, J., OLIVIER, C., GIMENO, F., and MANZANO, L. (1995). Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 75, 2720-2726.
20. LOWENSTEIN, C.J., DINERMAN, J.L., and SNYDER, S.H. (1994). Nitric oxide: a physiologic messenger. Ann. Intern. Med. 120, 227-237.
21. DELICONSTANTINOS, G., VILLIOTOU, V., and STAVRIDES, J.C. (1995). Release by ultraviolet B (u.v. B) radiation of nitric oxide (NO) from human keratinocytes: a potential role for nitric oxide in erythema production. Br. J. Pharmacol. 114, 1257-1265.
22. BECKMAN, J.S., and CROW, J.P. (1993). Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 21, 330-334.
23. DELICONSTANTINOS, G., VILLIOTOU, V., and STAVRIDES, J.C. (1995). Modulation of particulate nitric oxide synthase activity and peroxynitrite synthesis in cholesterol enriched endothelial cell membranes. Biochem. Pharmacol. 49, 1589-1600.
24. MILLS, C.D., SHEARER, J., EVANS, R., and CALDWELL, M.D. (1992). Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 149, 2709-2714.
25. LANGREHR, J.M., HOFFMAN, R.A., LANCASTER, J.R., Jr., and SIMMONS, R.L. (1993). Nitric oxide - a new endogenous immunomodulator. Transplantation 55, 1205-1212.
26. ANGGARD, E. (1994). Nitric oxide: mediator, murderer and medicine. Lancet 343, 1199-1205.
27. MITROPOULOS, D., PETSIS, D., KIROUDI, A., KYRIAKOU, G., RASDAN, A., ZERVAS, A., and DIMOPOULOS, C. (2000). The effect of intravesical bacillus Calmette-Guerin (BCG) instillations on the expression of inducible nitric oxide synthase (iNOS) in humans. Eur. Urol. 38, 516.
28. GORGOULIS, V.G., ZACHARATOS, P., KOTSINAS, A., LILOGLOU, T., KYROUDI, A., VESLEMES, M., RASSIDAKIS, A., HALAZONETIS, T.D., FIELD, J.K., and KITTAS, C. (1998). Alterations of p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am. J. Pathol. 153, 1749-1765.
29. DELICONSTANTINOS, G., VILLIOTOU, V., and STAVRIDES, J.C. (1996). Nitric oxide and peroxynitrite released by ultraviolet B-irradiated human endothelial cells are possibly involved in skin erythema and inflammation. Exp. Physiol. 81, 1021-1033.
30. GROSS, S.S., and WOLIN, M.S. (1995). Nitric oxide: pathophysiological mechanisms. Annu. Rev. Physiol. 57, 737-740.
31. ISCHIROPOULOS, H., ZHU, L., CHEN, Z., TSAI, M., MARTIN, J.C., SMITH, C.D., and BECKMAN, J.S. (1992). Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431-437.
32. VAN DER VLIET, A., EISERICH, J.P., O'NEIL, C.A., HALLIWELL, B., and GROSS, C.E. (1995). Tyrosine modification by reactive nitrogen species: a closer look. Arch. Biochem. Biophys. 319, 341-349.
33. MORCOS, E., JANSSON, D.T., ADOLFSON, J., KRATZ, G., and WIKLUND, N.P. (1999). Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 53, 1252-1257.
34. TUBARO, E., CAVALLO, G., CIFONE, M.G., FESTUCCIA, C., CHESSA, M.A., PENSA, V., and SANTONI, A. (1992). Nitric oxide production by lymphokine-activated killer cells: possible correlation with cytotoxic activity. In: The Biology of Nitric Oxide. S. Moncada, M.A. Marletta, J.B. Hibbs, Jr., and E.A. Higgs (eds.) Portland Press, 2, 168-170.
35. OLD, L.J. (1981). Cancer immunology: the search for specificity. Cancer Res. 41, 361-375.
36. URBAN, J.L., BURTON, R.C., HOLLAND, J.M., KRIPKE, M.L., and SCHRIEBER, H. (1982). Mechanisms of syngeneic tumor resection: susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155, 557-573.
37. BUBENIK, J., KIELER, J., TROMHOLT, V., HERMANN, G., and JANDLOVA, T. (1988). Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol. Lett. 18, 115-118.
38. RICHNER, J., AMBINDER, E.P., HOFFMAN, K., FEUER, E.J., and BEKESI, G. (1991). Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients. Cancer Immunol. Immunother. 34, 138-142.
39. KAVER, I., PECHT, M., TRAININ, N., GREENSTEIN, A., and BRAF, Z. (1992). T lymphocyte subsets and function in the peripheral blood of patients with urological cancer. Oncology 49, 108-113.
40. TSUJIHASHI, H., UEJIMA, S., AKIYAMA, T., and KURITA, T. (1989). Immunohistochemical detection of tissue-infiltrating lymphocytes in bladder tumors. Urol. Int. 44, 5-9.
41. FLAMM, J. (1992). Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer. Urology 40, 180-185.
42. STRAVORAVDI, P., BELIVANIS, J., DIMOPOULOS, T., HADZIGIANNIS, J., and POLYZONIS, M. (1992). The ultrastructure of the noninvolved urothelium of tumor-bearing patients before and after interferon treatment. J. Interferon Res. 12, 397-402.
43. STRAVORAVDI, P., NATSIS, K., KIRTSIS, P., RETALIS, G., KONSTANTINIDIS, E., and POLYZONIS, M. (1996). Ultrastuctural study of the uninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy. Eur. Urol. 29, 477-482.
44. STRAVORAVDI, P., NATSIS, K., KIRTSIS, P., TOLIOU, P., KONSTANTINIDIS, E., BARICH, A., and POLYZONIS, M. (1996). Ultrastuctural study of the urothelial lysosomal system in patients with transitional cell carcinoma after transurethral resection and interferon therapy. J. Exp. Ther. Oncol. 1, 222-225.